Advances in Gene Therapies and Treatment Strategies for X-Linked Retinitis Pigmentosa
Location
Suwanee, GA
Start Date
17-4-2026 12:00 PM
End Date
17-4-2026 1:00 PM
Description
Introduction: Retinitis pigmentosa (RP) is a group of inherited retinal degenerative disorders characterized by progressive loss of photoreceptors and irreversible vision impairment. Among its subtypes, X-linked retinitis pigmentosa (XLRP) is one of the most severe forms and is most commonly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. RPGR plays a critical role in photoreceptor ciliary transport and structural stability. Degeneration typically begins with rod photoreceptors, leading to night blindness (nyctalopia) and progressive peripheral visual field constriction, followed by secondary cone degeneration that ultimately compromises central vision. Although no definitive cure currently exists, recent advances in gene therapy have introduced promising therapeutic strategies for inherited retinal diseases.
Objective: The objective of this review is to examine current research on RPGR-targeted gene replacement therapies for X-linked retinitis pigmentosa and evaluate their potential to preserve retinal structure and function.
Methods: A review of the current literature was conducted to evaluate therapeutic advances in retinitis pigmentosa. Articles were identified using the search engines PubMed and Google Scholar with key terms including retinitis pigmentosa, X-linked retinitis pigmentosa, gene therapy, Luxturna, CRISPR, and optogenetics. To identify the most recent developments in clinical translation and regulatory progress, additional information was obtained from ClinicalTrials.gov and the U.S. Food and Drug Administration (FDA) databases.
Results: Preclinical studies in animal models demonstrated preservation of outer nuclear layer thickness and improvements in retinal function following AAV-mediated delivery of the RPGR gene. These findings supported the translation of RPGR gene therapy into clinical studies. Early-phase clinical trials using subretinal injection of AAV vectors carrying the RPGR gene have reported favorable safety profiles and encouraging signs of efficacy. Several treated patients showed improvements in retinal sensitivity and functional vision measures. However, some trials reported dose-related ocular inflammation, highlighting the importance of optimizing dosing strategies and immune management in future studies.
Conclusion: Current evidence suggests that RPGR gene replacement therapy represents a promising disease-modifying strategy for X-linked retinitis pigmentosa. Preclinical and early clinical data demonstrate the potential to slow photoreceptor degeneration and preserve visual function. Nevertheless, additional research is required to refine treatment parameters, evaluate long-term durability, and determine therapeutic effectiveness across different stages of disease progression. Continued investigation will be essential to fully establish RPGR gene therapy as a viable clinical treatment for XLRP.
Embargo Period
5-13-2026
Advances in Gene Therapies and Treatment Strategies for X-Linked Retinitis Pigmentosa
Suwanee, GA
Introduction: Retinitis pigmentosa (RP) is a group of inherited retinal degenerative disorders characterized by progressive loss of photoreceptors and irreversible vision impairment. Among its subtypes, X-linked retinitis pigmentosa (XLRP) is one of the most severe forms and is most commonly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. RPGR plays a critical role in photoreceptor ciliary transport and structural stability. Degeneration typically begins with rod photoreceptors, leading to night blindness (nyctalopia) and progressive peripheral visual field constriction, followed by secondary cone degeneration that ultimately compromises central vision. Although no definitive cure currently exists, recent advances in gene therapy have introduced promising therapeutic strategies for inherited retinal diseases.
Objective: The objective of this review is to examine current research on RPGR-targeted gene replacement therapies for X-linked retinitis pigmentosa and evaluate their potential to preserve retinal structure and function.
Methods: A review of the current literature was conducted to evaluate therapeutic advances in retinitis pigmentosa. Articles were identified using the search engines PubMed and Google Scholar with key terms including retinitis pigmentosa, X-linked retinitis pigmentosa, gene therapy, Luxturna, CRISPR, and optogenetics. To identify the most recent developments in clinical translation and regulatory progress, additional information was obtained from ClinicalTrials.gov and the U.S. Food and Drug Administration (FDA) databases.
Results: Preclinical studies in animal models demonstrated preservation of outer nuclear layer thickness and improvements in retinal function following AAV-mediated delivery of the RPGR gene. These findings supported the translation of RPGR gene therapy into clinical studies. Early-phase clinical trials using subretinal injection of AAV vectors carrying the RPGR gene have reported favorable safety profiles and encouraging signs of efficacy. Several treated patients showed improvements in retinal sensitivity and functional vision measures. However, some trials reported dose-related ocular inflammation, highlighting the importance of optimizing dosing strategies and immune management in future studies.
Conclusion: Current evidence suggests that RPGR gene replacement therapy represents a promising disease-modifying strategy for X-linked retinitis pigmentosa. Preclinical and early clinical data demonstrate the potential to slow photoreceptor degeneration and preserve visual function. Nevertheless, additional research is required to refine treatment parameters, evaluate long-term durability, and determine therapeutic effectiveness across different stages of disease progression. Continued investigation will be essential to fully establish RPGR gene therapy as a viable clinical treatment for XLRP.